CohBar Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at American Diabetes Association 78th Scientific Sessions

Jun 25, 2018

CohBar Announces the Appointment of Dr. Philippe Calais to its Board

Jun 7, 2018

CohBar to Hold 2018 Annual Shareholder Meeting and Investor Update, June 19, 2018

Jun 6, 2018

CohBar to Present CB4211 Novel Mechanism of Action at American Diabetes Association 78th Scientific Sessions

May 29, 2018

CohBar, Inc. Announces First Quarter 2018 Financial Results

May 15, 2018

CohBar, Inc. Announces Voluntary Delisting from the TSX Venture Exchange

Apr 18, 2018

CohBar, Inc. Announces Closing of Private Placement for Aggregate Gross Proceeds of Approximately $3,900,000

Apr 13, 2018

CohBar, Inc. Announces Fourth Quarter 2017 Financial Results

Apr 2, 2018

CohBar, Inc. Announces Closing of First Tranche of Private Placement

Mar 29, 2018

CohBar, Inc. Announces Financing of up to US$5,000,000 in Unsecured Promissory Notes

Mar 26, 2018